Korro Bio Financials - Benzinga

SPY766.53+0.30%QQQ742.00+0.55%BTC/USD83,972.30+0.41%DIA511.04−0.36%GLD380.73−0.56%TLT77.58−0.84%

Korro Bio Inc

KRRONASDAQ

Trade with Public

Trade with Public

$9.82

0.262.72%

Last update: Sep 30, 1:27 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Korro Bio Financials

Korro Bio (KRRO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Korro Bio Q2 EPS $(1.07) Beats $(1.31) Estimate

Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.31) by 18.32 percent. This is a 60.95 percent increase over losses of $(2.74) per share from the

Benzinga Newsdesk

PRO
Korro Bio Q1 EPS $(1.69) Beats $(2.17) Estimate

Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.69) per share which beat the analyst consensus estimate of $(2.17) by 22.12 percent. This is a 32.13 percent increase over losses of $(2.49) per share from the

Benzinga Newsdesk

Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook

Korro Bio stock rises after earnings as analysts upgrade outlook, highlight new drug candidate, and long-term growth plans.

Vandana Singh

PRO
Korro Bio Q4 EPS $(5.32) Misses $(2.05) Estimate, Sales $1.290M Beat $670.000K Estimate

Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(5.32) per share which missed the analyst consensus estimate of $(2.05) by 159.39 percent. This is a 135.4 percent decrease over losses of $(2.26) per share from the

Benzinga Newsdesk

Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results

Avi Kapoor

Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Results

Avi Kapoor

© 2026 Benzinga | All Rights Reserved